Welcome to the new scientist and researcher reference section. Your one-stop shop for the essential resources you need to advance your career.
The SNMMI Future Leaders Academy training focuses on setting a clear plan for increasing leadership abilities by developing the necessary skills and organizational expertise to enhance performance and ultimately evolve into a leader both within the nuclear medicine and molecular imaging community and the society.
SNMMI educational programs are designed to meet the professional development needs of scientists involved in nuclear medicine and molecular imaging endeavors.
The most up-to-date and comprehensive source for nuclear medicine coding and reimbursement information on the web. Please note that ALL information and materials within the SNMMI Coding Corner are direct products of the SNMMI Coding and Reimbursement Working Group.
For Hospitals (APCs, IPPS) Find general coding and reimbursement information for hospitals.
For Private Practices (RBRVS) Find general coding and reimbursement information for professionals in private practices.
Coding and Reimbursement Q&A This easy to use feature contains over 100 questions and answers related to topics such as cardiac, endocrine, neurology, nuclear medicine-related drugs, oncology, PET, PET/CT, radiopharmaceuticals, and more!
In nuclear medicine and molecular imaging, small amounts of radioactive agents are administered to the patient to allow the physician to examine molecular processes within the body. These procedures are highly effective, safe and painless diagnostic tools that present physicians with a detailed view of what’s going on inside an individual’s body at the cellular level. For more than 60 years, these studies have been used to evaluate practically all systems within the body, including the heart and brain, as well as to image many types of cancer.
SNMMI has a large body of knowledge in dose optimization that is continually growing and developing. The dose optimization website presents a wide variety of resources, including SNMMI journal articles, educational offerings, media-related information, links to useful websites and more.
The goal of the SNMMI Best Practices in Preclinical Imaging Initiative is to provide guidelines based on the community experience in designing and conducting preclinical imaging experiments.
Available Resources Include:
SNMMI's Center for Molecular Imaging Innovation and Translation is an organizational component within the SNMMI that is dedicated to all aspects of molecular imaging in the detection and management of disease. The center is currently facilitating initiatives to bring molecular imaging discoveries from the lab to the patient and to advance "personalized" medicine.
The Clinical Trials Network’s mission is to advance the use of molecular imaging radiopharmaceuticals in clinical trials through standardization of chemistry and imaging methodology. This includes using imaging radiopharmaceuticals during the course of drug development, as well as bringing new agents to regulatory approval. Click here to learn more about the CTN’s Oncology and Neurology Scanner Validation programs, ongoing efforts to harmonize reconstruction parameters in oncology clinical trials, and other services that CTN offers to help scientists advance their research.
The practice guidelines help to identify those elements of the procedure that are most important in obtaining a high-quality examination, while simultaneously controlling costs. Use of standardized procedures will increase the applicability of clinical research among multiple institutions, in turn, increasing the value of research studies, particularly in the field of technology assessment. In the interest of creating strong, comprehensive documents, some guidelines were formally adopted by SNMMI in collaboration with other professional organizations.
Amyloid imaging can tell Alzheimer’s disease (AD) and frontotemporal dementia (FTD) apart because FTD typically does not show the same pattern of amyloid, right? Not so fast, say brain researchers.
(MI: Making a Difference)
SNMMI and ERF are pleased to announce that David Douglas, MD and Benjamin Franc, MD are the recipients of the 2015 Robert E. Henkin Fellowship.
(Government Relations News)
The ALSYMPCA trial was a phase III randomized, double-blind, placebo-controlled trial published in 2013 which demonstrated an overall survival benefit and increased time to a first skeletal-related event with the administration of radium-223 to men with metastatic CRPC with multiple symptomatic bony metastases.
(MI: Making a Difference)
Using a battery of imaging and cognitive tests, Johns Hopkins specialists have gathered evidence of accumulated brain damage that may be linked to specific memory deficits experienced by former National Football League players decades after retirement.
(MI: Making a Difference)
This congress—co-sponsored by SNMMI and Johns Hopkins Medicine—will provide updates on recent developments in the field of Theranostics for NETs, Prostate Cancer, and beyond. Experts from around the world will discuss their research and experience in this exciting field.
Learn more about journals published by or sponsored by the Society of Nuclear Medicine and Molecular Imaging.
Tools, supported by evidence, to harmonize the practice of nuclear medicine using a progressive and safe approach.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the National Cancer Institute (NCI) held a joint workshop—NCI-SNMMI Workshop on Targeted Radionuclide Therapy—on October 24-25, 2014, at the National Institutes of Health (NIH) in Bethesda, Md.